Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Companyâs offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
äŒæ¥ã³ãŒãSLGL
äŒç€ŸåSol Gel Technologies Ltd
äžå Žæ¥Feb 01, 2018
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°34
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 01
æ¬ç€Ÿæåšå°Golda Meir 7
éœåžNESS-ZIONA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·- -
é»è©±çªå·97289313433
ãŠã§ããµã€ãhttp://www.sol-gel.com
äŒæ¥ã³ãŒãSLGL
äžå Žæ¥Feb 01, 2018
æé«çµå¶è²¬ä»»è
ãCEOã- -
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã